Systemic antibiotic treatment in upper and lower respiratory tract infections: official French guidelines Agence Française de Sécurité, Sanitaire des.

Slides:

Advertisements

Similar presentations

Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages

Advertisements

Systemic antibiotic treatment in upper and lower respiratory tract infections: official French guidelines Agence Française de Sécurité, Sanitaire des.

Laboratory diagnosis and biosafety issues of biological warfare agents

Rectal bacteriotherapy for recurrent Clostridium difficile-associated diarrhoea: results from a case series of 55 patients in Denmark 2000–2012 M. Tvede,

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

Rapid streptococcal testing for sore throat and antibiotic resistance

Benchmarking inappropriate empirical antibiotic treatment

C.N. van Ettekoven, D. van de Beek, M.C. Brouwer

Approach to diagnosis of infective endocarditis

Anthrax, tularemia, plague, ebola or smallpox as agents of bioterrorism: recognition in the emergency room B.A. Cunha Clinical Microbiology and Infection

Herpes zoster in non-hospitalized children

Atypical respiratory pathogens

Seven-day antibiotic courses have similar efficacy to prolonged courses in severe community-acquired pneumonia—a propensity-adjusted analysis G. Choudhury,

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

Therapy of acute gastroenteritis: role of antibiotics

Rapid streptococcal testing for sore throat and antibiotic resistance

How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development R. Bax Clinical Microbiology.

Telithromycin 800 mg once daily for seven to ten days is an effective and well-tolerated treatment for community-acquired pneumonia C. Carbon, S. Moola,

How to evaluate and predict the epidemiologic impact of antibiotic use in humans: the pharmacoepidemiologic approach D. Guillemot Clinical Microbiology.

Trends in antibiotic prescribing in general internal medicine wards: antibiotic use and indication for prescription B. Maraha, M. Bonten, H. Fiolet,

N.C. Weightman, S. Mitra, P.T. Kipling

Structure of grepafloxacin relative to activity and safety profile

Vector control: a cornerstone in the malaria elimination campaign

Meropenem versus imipenem/cilastatin as empirical monotherapy for serious bacterial infections in the intensive care unit C. Verwaest Clinical Microbiology.

C-3′Quaternary Ammonium Cephems, a New Wave of Cephalosporins

Training for the infectious diseases speciality in Norway

F. Grill, P. Muñoz, R. Jofre, E. Bouza

G. Höffken Clinical Microbiology and Infection

Community-acquired pneumonia: the evolving challenge

Predicted effects on antibiotic use following the introduction of British or North American guidelines for community-acquired pneumonia in The Netherlands

Does it make sense to detect Streptococcus pyogenes during tonsillitis in Europe to prevent acute rheumatic fever? S. Edouard, A. Michel-Lepage, D. Raoult

Laboratory diagnosis and biosafety issues of biological warfare agents

Comparative in vitro activity of ertapenem against bacterial pathogens isolated from patients with lower respiratory tract infections P.S. Hicks, B.

Effects of gentamicin monotherapy for the initial treatment of community-onset complicated non-obstructive acute pyelonephritis due to Enterobacteriaceae.

Changes in macrolide resistance among respiratory pathogens after decreased erythromycin consumption in Taiwan P.-R. Hsueh, J.-M. Shyr, J.-J. Wu Clinical.

In vitro selection of antibiotic resistance in Pseudomonas aeruginosa

Levofloxacin in the treatment of ventilator-associated pneumonia

R. Bitterman, M. Paul, D. Polak, Y. Geffen

Effect of antioxidants on the immune response of Helicobacter pylori

Laboratory diagnosis of Clostridium difficile disease

Recent developments in staphylococcal scalded skin syndrome

G.R. Davies Clinical Microbiology and Infection

A. Bryskier Clinical Microbiology and Infection

T.M. File Clinical Microbiology and Infection

Incidence of Hajj-associated febrile cough episodes among French pilgrims: a prospective cohort study on the influence of statin use and risk factors

Community-acquired pneumonia: epidemiologic and clinical consideration

Benchmarking inappropriate empirical antibiotic treatment

Vaccinations against respiratory tract infections at Hajj

Reducing antibiotic use in influenza: challenges and rewards

Clinical infection services—the Leiden experience

Ethan Rubinstein, Itzhak Levy Clinical Microbiology and Infection

Statin use and clinical outcomes among pneumonia patients

Clinical Microbiology and Infection

Clinical Microbiology and Infection

W. Eugene Sanders, Christine C. Sanders

Overview of cefixime use in community-acquired infections

Nebulized hypertonic saline treatment in hospitalized children with moderate to severe viral bronchiolitis Z. Luo, Z. Fu, E. Liu, X. Xu, X. Fu, D. Peng,

Sanford Chodosh Clinical Microbiology and Infection

K. Kaier, N.T. Mutters, U. Frank Clinical Microbiology and Infection

The atypical pneumonias: clinical diagnosis and importance

Facilitating learning and change in physicians: Implications for a system of continuing medical education in Europe Robert D. Fox Clinical Microbiology.

Abstracts Clinical Microbiology and Infection

New oral cephalosporins in pediatric community-acquired infections

Moving from recommendation to implementation and audit: Part 1

Carratalà J. Clinical Microbiology and Infection

J.L. Balcázar Clinical Microbiology and Infection

New patterns of HIV-1 resistance during HAART

Joshua P. Metlay, Daniel E. Singer Clinical Microbiology and Infection

Impact of antibiotic restrictions: the patient's perspective

The future of diagnostic bacteriology

Presentation transcript:

Systemic antibiotic treatment in upper and lower respiratory tract infections: official French guidelines Agence Française de Sécurité, Sanitaire des Produits de Santé Clinical Microbiology and Infection Volume 9, Issue 12, Pages 1162-1178 (December 2003) DOI: 10.1111/j.1469-0691.2003.00798.x Copyright © 2003 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 1 Current approach to treating common cold. *Respiratory discomfort, fever persisting more than 3 days or occuring after this period, persistence of the other symptoms (cough, rhinorrhoea, nasal obstruction) after 10 days with no signs of improvement, irritability, nocturnal awakening, otalgia, otorrhoea, purulent conjunctivitis, palpebral oedema, gastrointestinal disorders (anorexia, vomiting, diarrhoea) and skin rash. Clinical Microbiology and Infection 2003 9, 1162-1178DOI: (10.1111/j.1469-0691.2003.00798.x) Copyright © 2003 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 2 Practical approach to treating pharyngitis. Clinical Microbiology and Infection 2003 9, 1162-1178DOI: (10.1111/j.1469-0691.2003.00798.x) Copyright © 2003 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 3 Initial therapeutic strategy in community-acquired pneumonia (without risk factor and without serious symptoms). Clinical Microbiology and Infection 2003 9, 1162-1178DOI: (10.1111/j.1469-0691.2003.00798.x) Copyright © 2003 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 4 Secondary therapeutic strategy in community-acquired pneumonia (without risk factor or serious symptoms). *amoxicillin macrolides; more rarely : either amoxicillin + macrolide, either : telithromycin or fluoroquinolone active against pneumococcus. Clinical Microbiology and Infection 2003 9, 1162-1178DOI: (10.1111/j.1469-0691.2003.00798.x) Copyright © 2003 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 5 Diagnostic and therapeutic elements of respiratory tract infections in children Clinical Microbiology and Infection 2003 9, 1162-1178DOI: (10.1111/j.1469-0691.2003.00798.x) Copyright © 2003 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 6 Therapeutic regimen for community-acquired pneumonia in children without risk factors Clinical Microbiology and Infection 2003 9, 1162-1178DOI: (10.1111/j.1469-0691.2003.00798.x) Copyright © 2003 European Society of Clinical Infectious Diseases Terms and Conditions